Ameriprise Financial Inc. lowered its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 20.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 97,885 shares of the company's stock after selling 24,717 shares during the period. Ameriprise Financial Inc. owned 0.29% of TransMedics Group worth $6,103,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in TMDX. Atlas Capital Advisors Inc. acquired a new position in TransMedics Group during the fourth quarter worth $31,000. Hager Investment Management Services LLC bought a new stake in shares of TransMedics Group in the 4th quarter valued at about $33,000. Sachetta LLC acquired a new stake in TransMedics Group in the 4th quarter valued at about $40,000. AlphaQuest LLC bought a new position in TransMedics Group during the fourth quarter worth about $52,000. Finally, Arcadia Investment Management Corp MI bought a new position in TransMedics Group during the fourth quarter worth about $72,000. Institutional investors own 99.67% of the company's stock.
TransMedics Group Stock Performance
TransMedics Group stock traded up $4.28 during midday trading on Tuesday, hitting $128.53. The company's stock had a trading volume of 1,010,231 shares, compared to its average volume of 1,357,988. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a market cap of $4.35 billion, a price-to-earnings ratio of 136.74 and a beta of 1.91. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37. The company has a 50-day moving average price of $90.64 and a two-hundred day moving average price of $77.44.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. The company had revenue of $143.54 million during the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm's quarterly revenue was up 48.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.35 earnings per share. As a group, sell-side analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of research firms have recently issued reports on TMDX. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research report on Wednesday, April 23rd. Oppenheimer upped their price objective on shares of TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Finally, Piper Sandler reissued an "overweight" rating and issued a $125.00 price objective (up from $105.00) on shares of TransMedics Group in a research report on Friday, May 9th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $126.70.
Read Our Latest Research Report on TransMedics Group
Insider Buying and Selling at TransMedics Group
In other TransMedics Group news, Director Edward M. Basile sold 6,000 shares of the firm's stock in a transaction dated Friday, May 9th. The shares were sold at an average price of $115.63, for a total value of $693,780.00. Following the transaction, the director now directly owns 732 shares of the company's stock, valued at $84,641.16. This trade represents a 89.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Weill sold 732 shares of the business's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total transaction of $90,680.16. Following the completion of the transaction, the director now owns 12,134 shares of the company's stock, valued at $1,503,159.92. The trade was a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.00% of the company's stock.
About TransMedics Group
(
Free Report)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Featured Articles
Before you consider TransMedics Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.
While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
